Gene Therapy for Duchenne muscular dystrophy.

Area of Science:

• Biomedical research
• Gene therapy
• Neuromuscular disorders

Background:

• Duchenne muscular dystrophy (DMD) is a genetic disorder resulting from deficient dystrophin protein expression.
• Restoring dystrophin production is the most direct therapeutic strategy for DMD.
• Recent advancements enhance the potential for successful gene therapy interventions.

Purpose of the Study:

• To summarize promising developments in gene therapy for DMD.
• To provide an overview of adeno-associated virus (AAV) vector-based gene therapy for DMD.
• To identify critical issues for large-scale therapeutic implementation.

Main Methods:

• Literature review via PubMed searches.
• Analysis of scientific conference proceedings.
• Inclusion of own laboratory findings.

Main Results:

• Adeno-associated virus (AAV) vectors show promise for bodywide dystrophin restoration in DMD patients.
• Micro-dystrophin delivery via AAV vectors is a leading therapeutic approach.
• Potential for treating all DMD patients with AAV-based gene therapy.

Conclusions:

• AAV-mediated micro-dystrophin gene therapy is the most direct and promising treatment for DMD.
• Ensuring safe and efficient delivery of micro-dystrophin is crucial.
• Minimizing immune responses to the therapy is a significant challenge.